eli lilly zepbound - Search News

News

Eli Lilly, Novo Nordisk

Forbes · 19h

Eli Lilly: 50% Upside For LLY Stock?

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Fast Company on MSN · 1d

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

The Financial Times · 1d

Eli Lilly obesity pill disappoints and gives boost to arch-rival Novo Nordisk

Shares in US-based Lilly fell 14.2 per cent on the trial results, while stock in Danish arch-rival Novo Nordisk, the maker of the pioneering Ozempic weight-loss drug, rose 6.7 per cent. Novo Nordisk has been losing share to Lilly in the US in injectable weight-loss drugs.

Eli Lilly weight loss pill shows promise

CBS News on MSN · 1d

Eli Lilly weight loss pill shows promise in latest clinical trial, company says

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

UPI on MSN · 13h

Initial results show promise for Eli Lilly's new weight loss drug

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount of weight, the company said.

Indianapolis Star on MSN · 15h

Eli Lilly closer to breakthrough weight loss drug; shares tumble as some question results

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

1don MSN

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...

17hon MSN

Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

24d

Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Marketplace2d

Makers of Wegovy, Zepbound face competition from compounding pharmacies

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Zacks Investment Research on MSN4d

Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings?

Eli Lilly and Company LLY will report its second-quarter earnings on Aug. 7, before market open. The Zacks Consensus Estimate ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results